Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission : a study by the acute leukemia working party of the EBMT. / Gilleece, Maria H.; Shimoni, Avichai; Labopin, Myriam; Robinson, Stephen; Beelen, Dietrich; Socié, Gerard; Unal, Ali; Ganser, Arnold; Vitek, Antonin; Sengeloev, Henrik; Yakoub-Agha, Ibrahim; Tholouli, Eleni; Polge, Emmanuelle; Mohty, Mohamad; Nagler, Arnon.
I: Blood Cancer Journal, Bind 11, Nr. 5, 88, 2021.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission
T2 - a study by the acute leukemia working party of the EBMT
AU - Gilleece, Maria H.
AU - Shimoni, Avichai
AU - Labopin, Myriam
AU - Robinson, Stephen
AU - Beelen, Dietrich
AU - Socié, Gerard
AU - Unal, Ali
AU - Ganser, Arnold
AU - Vitek, Antonin
AU - Sengeloev, Henrik
AU - Yakoub-Agha, Ibrahim
AU - Tholouli, Eleni
AU - Polge, Emmanuelle
AU - Mohty, Mohamad
AU - Nagler, Arnon
N1 - Publisher Copyright: © 2021, The Author(s).
PY - 2021
Y1 - 2021
N2 - Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation registry assessed HCT outcomes by declared MRD status in a cohort of 1042 adult patients with AML CR2 at HCT. Patients were transplanted 2006–2016 from human leukocyte antigen (HLA) matched siblings (n = 719) or HLA 10/10 matched unrelated donors (n = 293). Conditioning was myeloablative (n = 610) or reduced-intensity (n = 432) and 566 patients (54%) had in-vivo T cell depletion. At HCT, 749 patients (72%) were MRD negative (MRD NEG) and 293 (28%) were MRD positive (MRD POS). Time from diagnosis to HCT was longer in MRD NEG than MRD POS patients (18 vs. 16 months (P < 0.001). Two-year relapse rates were 24% (95% CI, 21–28) and 40% (95% CI, 34–46) in MRD NEG and MRD POS groups (P < 0.001), respectively. Leukemia-free survival (LFS) was 57% (53–61) and 46% (40–52%), respectively (P = 0.001), but there was no difference in terms of overall survival. Prognostic factors for relapse and LFS were MRD NEG status, good risk cytogenetics, and longer time from diagnosis to HCT. In-vivo T cell depletion predicted relapse.
AB - Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation registry assessed HCT outcomes by declared MRD status in a cohort of 1042 adult patients with AML CR2 at HCT. Patients were transplanted 2006–2016 from human leukocyte antigen (HLA) matched siblings (n = 719) or HLA 10/10 matched unrelated donors (n = 293). Conditioning was myeloablative (n = 610) or reduced-intensity (n = 432) and 566 patients (54%) had in-vivo T cell depletion. At HCT, 749 patients (72%) were MRD negative (MRD NEG) and 293 (28%) were MRD positive (MRD POS). Time from diagnosis to HCT was longer in MRD NEG than MRD POS patients (18 vs. 16 months (P < 0.001). Two-year relapse rates were 24% (95% CI, 21–28) and 40% (95% CI, 34–46) in MRD NEG and MRD POS groups (P < 0.001), respectively. Leukemia-free survival (LFS) was 57% (53–61) and 46% (40–52%), respectively (P = 0.001), but there was no difference in terms of overall survival. Prognostic factors for relapse and LFS were MRD NEG status, good risk cytogenetics, and longer time from diagnosis to HCT. In-vivo T cell depletion predicted relapse.
U2 - 10.1038/s41408-021-00479-3
DO - 10.1038/s41408-021-00479-3
M3 - Journal article
C2 - 33980810
AN - SCOPUS:85105791413
VL - 11
JO - Blood Cancer Journal
JF - Blood Cancer Journal
SN - 2044-5385
IS - 5
M1 - 88
ER -
ID: 303604162